Ben Lamm
Co-founder and CEO, Colossal Biosciences. On 1 show, 1 appearance. The Shows tab opens the full record on each.
founderexecutiveinvestor@BenLamm ↗LinkedIn ↗colossal.com ↗Wikipedia ↗
Ben Lamm is an entrepreneur who co-founded Colossal Biosciences alongside geneticist George Church, leading efforts in de-extinction, genetic engineering, and species conservation. Prior to Colossal, he founded and exited several tech ventures, including Hypergiant Industries, Conversable, Team Chaos, and Chaotic Moon Studios.
1shows
1appearances
28statements
8resolved
2supported
2contradicted
25%fully supported
Everything Ben Lamm said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Lamm: Colossal could birth an extinct species within 12 months
“The next 12 months, I'm looking forward to Colossal potentially having the next birthed extinct species.”
Lamm: Colossal intends to release extinct and gene-edited species into the wild
“So our goal for our extinct species are genetically modified gene drives and even cloning of endangered species. All of that is to go into the wild, but we have to have government and indigenous and global support.”
Lamm: Woolly mice are second most genetically modified organisms behind dire wolves
“These are the second most genetically modified
Multicellular organisms on the planet after our direwolves.”
Lamm: ViaGen cloning efficiency reached 80% versus 2% industry norm
“Well, Viagen had like cloning efficiencies at 80%, or most people are at two percent, right?”
Lamm: Earth is forecasted to lose 50% of biodiversity within 25 years
“It's currently forecasted that we're going to lose up to 50% of all biodiversity in the next 25 years.”
Lamm: Colossal is educating USDA and defense agencies on genetic tech
“Like right now we are educating USDA, the intelligence community, the Department of War and others on these technologies and how they can combat these issues domestically and abroad.”
Lamm: Colossal could eradicate the screwworm problem in six to seven months
“Our solution, which is already made could eradicate the entire problem in every model that we've done in six to seven months.”
Lamm: Direct air carbon capture is a dumb climate solution
“So when we were solving these problems, if we are solving it in dumb ways, like, I think, you know, a lot of the air capture systems in other ways, the direct air caption carbon systems and others in a lot of other ways that we're trying to solve climate are d…”
Lamm: Academic research labs are underfunded, politicized, and dilapidated
“Go work back in academia where you're underfunded. It's all like massively politicized and it's massively competitive and your labs are like held up by pizza boxes, right?”
Ben Lamm: AI will enable a real-time digital twin of nature
“My hottest take right now is that I think AI is gonna converge, and, ah, we are going to build a digital twin of nature, and just like we have prediction models for, like, everything from, like, missile defense to, ah, tsunamis and earthquakes, we're gonna hav…”
Lamm: Colossal achieved world-record multiplex gene editing in healthy woolly mice
“We had a hundred percent healthy mice born with exactly the predicted phenotypes with the most multiplex edited delivered at one time ever.”
Lamm: Colossal grew mammoth hair follicles from elephant stem cells
“We actually have a hair follicles growing in, in where we've taken elephant stem cells and created follicles so that we can grow mammoth hair.”
Lamm: Colossal open-sources all of its technology for free for conservation
“And then lastly, we open source all of our technologies for conservation. So anybody can use any of our technologies for free for conservation.”
Colossal Biosciences targets thousands of multiplex gene edits simultaneously
“We're now pushing a new construct that we've designed and a new delivery mechanism that we think we can be doing thousands of edits at once.”
Lamm: Colossal will not work on humans or non-human primates
“So, so we won't work on humans here because we've been asked the Neanderthal question. And so non-human primates in over, we won't work on, right? Giant epithecus would be amazing to see, but we're not going to do that.”
Lamm: Selling animals is not on Colossal Biosciences' product roadmap
“We're not in the selling animal business. So therefore, it's not currently a part of our roadmap.”
Lamm: Colossal raised $635M total after $400M round oversubscribed
“Yeah, 6:35 total. The last round was supposed to be 200, and it got overscribed to 400.”
Lamm: Invasive species represent a half-trillion-dollar global problem
“So invasive species is like half a trillion dollar problem globally.”
Lamm: Colossal owns the world's largest elephant dataset
“Well, we have the largest data set on elephants in the entire world.”
Lamm: Colossal told investors inspiration matters as much as value creation
“So that, that, that like, so for us, and we told our investors this from day one, That inspiration needs to be as important as value creation, and you need to be on board with that. Like, if we do the greatest thing in the world that nobody knows about and lik…”
Lamm: Somatic cell nuclear transfer embryology will be automated with robotics
“But in the future, that whole process will be automated with robotics.”
Lamm: Claude Opus cannot perform ancestral state reconstruction or comparative genomics
“Turns out that like, you know, Opus doesn't do like an ancestral state reconstruction of like a genome and like it doesn't like build comparative genomics models.”
Lamm: Reprogramming scientists to use Jira was harder than reprogramming stem cells
“I think the hardest thing we've done is reprogram, not stem cells, but scientists to work in things like JIRA and Smartsheets, like traditional software, like things”
One line per show, most statements first. The link opens Ben's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 SOURCERYLEDGER | Co-founder and CEO, Colossal Biosciences | 1 | 28 | 25% 2/8 | full record on Sourcery → |